Equity Research, Broker Reports, and media content on Diaceutics Plc

  • Access the latest forecasts, broker valuations, multiples, and video content from the city about Diaceutics Plc
  • See live updates from analysts, company announcements, and other news in a personalised/single dashboard
Diaceutics
  • 09 Apr 24
Hybridan Small Cap Feast - 9 April 2024

9th April 2024 * A corporate client of Hybridan LLP ** Arranged by type of listing and date of announcement *** Alphabetically arranged **** Potential means Intention to Float (ITF) has been announced Dish of the day Admissions: Helix Exploration (HEX.L) a helium exploration company with operations in Montana, USA announces admission of its Ordinary Shares to trading on the AIM market of the London Stock Exchange. An Oversubscribed placing with book of demand over £22m to raise gross proceeds of

Companies: SUN ORCP HVO VLG LGRS DXRX CCS AEE

Hybridan
  • 05 Feb 24
Hot Off The Wires - The Day Ahead

Today's news and views, plus announcements from: VOD, SEIT, CMCX, DXRX, CUSN, TRR, & WINE.

Companies: TRR SEIT DXRX CUSN

Capital Access Group
  • 30 Jan 24
Hot Off The Wires - The Day Ahead

Today's news and views, plus announcements from: DGE, PETS, HILS, DEC, STEM, RWI, & DXRX.

Companies: Diaceutics Plc

Capital Access Group
  • 30 Jan 24
Diaceutics | FY23 update – 22% revenue growth, £16.7m YE cash

Diaceutics has released a trading statement for the year to December 2023 guiding to revenue growth of 22% YoY to £23.7m, up 19% on a constant currency basis. The order book jumped 57% to £26.6m, of which c£12.3m is expected to be realised in FY24, and which currently stands at £30.8m. The proportion of recurring revenue continues to increase and is now over 50% (FY22 35%). Cash at YE23 stood at £16.7m, indicating a near halving of the rate of cash burn in 2H23 compared to 1H23. We adjust our FY

Companies: Diaceutics Plc

Capital Access Group
  • 26 Sep 23
Hybridan Small Cap Feast - 26 Sep 23

26th September 2023 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment ob

Companies: TMG SNT QTX PEG PEG OBD JNEO EQT DXRX COG COG

Hybridan
  • 26 Sep 23
Diaceutics - HY Results & CEO Transition

Diaceutics reported interim results reflecting the trading update for revenue, growth and composition. The gross profit for the half was £8.7m, up 38% YoY generating a gross margin of 88% (1H22 84%), despite the pressure on pharma industry spend in 1H23 which has now reversed. We leave our forecasts unchanged but with increased confidence that they will be met or exceeded. The business continues to perform in line with the growth path forged by Peter Keeling, but after 18 years, Mr Keeling is to

Companies: Diaceutics Plc

Capital Access Group
  • 29 Aug 23
Hot Off The Wires - The Day Ahead

Today's news and views, plus announcements from: RIO, BNZL, IGG, BYG, & DXRX.

Companies: Rio Tinto plc (RIO:LON)Diaceutics Plc (DXRX:LON)

Capital Access Group
  • 25 Jul 23
Small Cap Feast 25 07 2023

Joiners: No joiners today. Leavers: No leavers today. What’s cooking in the IPO kitchen?** Announced ITF 12 July: Substrate Artificial Intelligence, an artificial intelligence company based in Spain that creates, buys and scales companies around AI in diverse sectors such as fintech, agritech, energy, human resources, and health, intends to join the Access Segment of the AQSE Growth Market. Announced ITF 6 July: Blackpoint Biotech plc, a medical cannabinoids company established to fulfil gaps in

Companies: ALU WYN AFRN TSTL DXSP AEO HVO DXRX

Hybridan
  • 25 Jul 23
Diaceutics - 1HFY23 trading statement - a strong performance

Diaceutics has released its trading statement for the half year to the end of June, ahead of the interim results to be published on 26 September. The company reported revenue growth of 32% YoY and growth in the order book of 43%. Cash and net cash ended the period at £17.9m and the company remains fully funded to execute the growth strategy it announced in January. Diaceutics is becoming the primary commercialisation partner for pharma companies launching precision medicines with 21 of the top 3

Companies: Diaceutics Plc

Capital Access Group
  • 05 Jun 23
Hybridan Small Cap Feast 5 June 2022

5th June 2023 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectiv

Companies: IRON SRES TSTL GTC ORCP DXRX CEG VRCI

Hybridan
  • 05 Jun 23
Diaceutics - $10m Contract Win

Diaceutics has announced a new US$10.1m multi-year enterprise engagement with a top 10 global pharma company covering a wide range of Diaceutics' subscription data services to be delivered via the company's DXRX platform. The three-year contract includes additional options which could result in a significant increase in the scope and value of the contract.

Companies: Diaceutics Plc

Capital Access Group
  • 21 Apr 23
Diaceutics (DXRX) Full Year 2022 Results presentation - April 2023
diaceutics-dxrx-full-year-2022-results-presentation-april-2023-21-04-2023
  • 17 Apr 23
Hybridan Small Cap Feast - 17 Apr 23

17 April 2023 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectiv

Companies: IGP RNO CNSL DXRX TEK SYS CER SUP

Hybridan
  • 17 Apr 23
Hot Off The Wires - The Day Ahead

Today's news and views, plus announcements from: GSK WG., ASHM, DXRX, BOOM, AVCT, TEK, UOG, & EBQ.

Companies: DXRX UOG AVCT

Capital Access Group
  • 17 Apr 23
Diaceutics - FY22 Results - April 2023

As flagged with the trading statement, Diaceutics reported a 40% YoY increase in revenue to £19.5m generating EBITDA of £3.6m, up 53% YoY with diluted EPS of 0.84p, up 27% YoY. More important in our view, was the structural change in revenue generation to a recurring revenue model with platform-based subscription contracts accounting for 35% of revenue up from 3% in 2021, driving the development of a meaningful forward order book of £16.9m (FY21 £1.7m) for the first time. Cash and net cash ended

Companies: Diaceutics Plc

Capital Access Group

Diaceutics Plc

Company Profile

  • Personnel:
  • Peter Keeling , CEO | Nick Roberts, CFO

Research, Charts & Company Announcements

Research Tree provides access to ongoing research coverage, media content and regulatory news on Diaceutics Plc. We currently have 167 research reports from 6 professional analysts.

Latest News/RNS

(more news)
Date Source Announcement
09Apr24 07:00 RNS Diaceutics PLC - Appointment of Amie Mc Neice as VP of Marketing
05Apr24 13:40 RNS Diaceutics PLC - Block Listing Return
03Apr24 07:00 RNS Diaceutics PLC - PDMR Shareholding/Share Incentive Plan
02Apr24 07:00 RNS Diaceutics PLC - Director/PDMR/PCA Shareholding & TR1
21Mar24 07:00 RNS Diaceutics PLC - Significant upgrade to Diaceutics' DXRX platform
19Mar24 07:00 RNS Diaceutics PLC - Diaceutics forms landmark industry Forum
07Mar24 07:00 RNS Diaceutics PLC - Director/PDMR Shareholding
Get free RNS email alerts

  • Frequency of research reports

     

  • Research reports on

    Diaceutics Plc

  • Providers covering

    Diaceutics Plc